# Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients

> **NCT00383708** · PHASE3 · COMPLETED · sponsor: **Ipsen** · enrollment: 125 (actual)

## Conditions studied

- Acromegaly

## Interventions

- **DRUG:** lanreotide (Autogel formulation)
- **DRUG:** Pegvisomant

## Key facts

- **NCT ID:** NCT00383708
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2008-10
- **Final completion:** 2008-10
- **Target enrollment:** 125 (ACTUAL)
- **Last updated:** 2022-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00383708

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00383708, "Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT00383708. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*